Group items tagged

The NHS England is rapidly expanding the targeted lung health check programme (TLHC) across England to detect lung cancers at an early stage. Launched in 2019, it is a national scheme that identifies people aged 55-74 at increased risk of lung cancer to invite them for a lung health check and chest CT scan, if appropriate. Since then, it has heled detect over 3,000 lung cancers, mostly at an early stage when the condition is more treatable, Dr Jason Page, Clinical Director of South Yorkshire and Bassetlaw targeted lung health checks, revealed in a blog on the NHS website. The decision to initiate the programme follows a study that showed CT screening reduced lung cancer mortality by 26 per cent in men and between 39 per cent and 61 per cent in women.

It is common knowledge that human happiness and well-being are dependent on good health. According to The American Lung Association (ALA) though, lung cancer is the most common cause of cancer-related death in men and women as well. Unfortunately, it seems we often overlook the importance of our lungs. We tend to forget that they are nature's natural defensive system designed to keep dirt and germs out. However, there are several crucial things you can do to lower your lung disease risk. Here are some valuable guidelines for keeping your lungs in good shape. 1. AVOID EXPOSURE TO POLLUTION 2. NO SMOKING! 3. KEEP AWAY FROM INFECTIONS 4. TAKE DEEP BREATHS 5. EXERCISE REGULARLY These are the most essential and valuable guidelines that you should follow if you want your respiratory system to be healthy. Along with proper exercise, maintaining a balanced diet, and keeping your mind in a healthy vigorous state, they should form the foundation for long and prosperous life. Let's always keep in mind the teachings of ancient Greek philosophers, like Hippocrates, who maintained the axiom "a healthy mind in a healthy body", and we'll always be on the right track.

AstraZeneca said on Thursday (June 30) that a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery. Data showed the combination was more effective in removing cancer cells in tissue samples taken during surgery when compared with just chemotherapy in patients with non-small cell lung cancer, the drugmaker said. The interim result is a boost to the company's oncology efforts - a major area of focus - following disappointing data for Imfinzi earlier in the year in another area of therapy. AstraZeneca added the trial would continue as planned to assess the additional main goal of event-free survival, and the interim data would be shared with health authorities globally. Imfinzi belongs to the immunotherapy class of treatments, which boost the body's defences to fight cancer by using antibodies that block or bind to foreign substances in the body. The treatment generated $2.41 billion in 2021 sales.

The drug, 'durvalumab', can double the overall time someone can survive with an aggressive form of lung cancer from two-and-a-half to five years. It has been approved by the National Institute for Health and Care Excellence (NICE) and the NHS has sealed a deal with manufacturer AstraZeneca to begin rolling it out. The new treatment will be offered to more than 550 patients a year with advanced non-small-cell lung cancer (NSCLC) who have already undergone both chemotherapy and radiotherapy concurrently. NHS said: "The drug can stop the cancer from getting worse for more than two years - significantly longer than treatment with a combination of chemotherapy and radiotherapy, which can only hold the disease at bay for around six months. This increases overall survival time and gives patients more precious moments with their loved ones." Dame Cally Palmer, national cancer director for NHS England, said: "We are resolute in our ambition to fight the devastating effects of cancer and new pioneering treatments like durvalumab are a vital lifeline for people living with cancer - giving them more precious time with family and friends.

'Tepotinib' has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC). The new potentially life-extending drug is available from Thursday (14 April). It has been recommended for routine use across the NHS in England through Project Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster. NICE has published its final appraisal document recommending tepotinib (also known as Tepmetko and produced by company Merck Serono Ltd) as an option for treating advanced NSCLC with METex14 skipping gene alterations in adults. People with METex14 skipping alterations of NSCLC make up between 1-2% of all adults with lung cancer in England. Tepotinib, which requires people to take two tablets once daily, provides a new targeted treatment for adults with METex14 skipping gene alterations. Just over 700 people in England would be eligible to receive tepotinib as either a first or second-line treatment.

Thousands of lung cancer patients in England will benefit from a ground-breaking new drug that can reduce the risk of relapse. This follows a deal brokered by NHS England and approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for atezolizumab therapy to treat non-small cell lung cancer (NSCLC). More than 850 patients are expected to be eligible for the drug in the first year, rising to more than 1000 in the third year. It is the first immunotherapy approved for patients with early-stage NSCLC who have undergone surgery and chemotherapy. Clinical trials have shown that atezolizumab can reduce the risk of cancer relapse or death by 34 per cent in patients with early-stage NSCLC.

Lung cancer is a significant health concern, and understanding its stages is crucial for effective diagnosis and treatment planning.

COPD consists of multiple lung infections and is considered incurable by most physicians. Can timely diagnosis, on the bright side, slow down its progress?

COPD consists of multiple lung infections and is considered incurable by most physicians. Can timely diagnosis, on the bright side, slow down its progress?

NHS cancer check has set a new record, despite pressures on hospitals due to Covid-19, the number of people being treated for the cancer remained higher than before the pandemic, revealed NHS. Over the last 12 months almost three million people were referred for cancer checks which is up by over a tenth on the 2.4 million people referred before the pandemic. "Even at the peak of the Omicron wave, referrals for suspected cancer were at 116 per cent of pre-pandemic levels with around 11,000 people getting checked every day over the last year," said NHS. In order to meet increasing demand for cancer checks, NHS services across the country are expanding their diagnostic capabilities through one stop shops for tests, mobile clinics and cancer symptom hotlines, ensuring people are diagnosed and treated as early as possible to give them a much better chance of beating the disease. More than 30,000 people every month are being invited for lung cancer checks through NHS mobile trucks visiting at risk communities across the country, as part of the biggest programme to improve early lung cancer diagnosis in health service history.

Lung cancer is a significant health concern, and understanding its stages is crucial for effective diagnosis and treatment planning.

Audio link How to know symptoms of Lung infection? What are the main effects and symptoms of the disease?

Audio link How to know symptoms of Pneumothorax lungs? What are the main effects and symptoms of the disease?

Diet, exercise, and stress management all play important roles in heart, lung, and brain health. however a recent report from the world Health Organization suggests that the positive effects of those healthy way decisions may be jeopardized by the straightforward act of taking a breath.

Approximately 2 billion people suffer from Tuberculosis each year. Tuberculosis or simply TB is an infectious and highly contagious disease of the body especially lungs. It spreads mainly via Mycobacterium tuberculosis which is a tough and highly resistant microbe.

Tuberculosis is a serious, infectious and often fatal disease of the lungs. It can also affect other parts of the body. But the most common type of Tuberculosis is pulmonary Tuberculosis. It is more common in women than in men. The causative agent is a Gram-positive bacterium (Mycobacterium tuberculosis).

Tuberculosis or simply TB is a spreadable disease caused by Mycobacterium tuberculosis. This organism has a hard, waxy cell wall that makes it highly resistant to unfavorable environments and drugs. It evades the mucus lining of the windpipe and enters the lungs.

The goal of treating Tuberculosis is to protect the patient from possible disability and death. Another objective is to reduce the spread of Tuberculosis infection to others. TB may be a stubborn infection but with the right measures at the right time, it can be cured.

The BCG vaccine (which stands for Bacillus Calmette-Guérin vaccine) protects against Tuberculosis, commonly known as TB. TB is a serious infection which affects the lungs, but it can affect other parts of the body such as the bones, joints and kidneys. It can also cause meningitis.

Đai lưng cột sống PresiTom là giải pháp bảo tồn cột sống lưng được các bác sĩ khuyên sử dụng nhiều nhất hiện nay. Vậy sự khác biệt của đai lưng cột sống PresiTom với các loại đai lưng trên thị trường là gì khiến các chuyên gia xương khớp đều khuyên sử dụng vậy?

Holy basil is known as the queen of herbs, it especially works in the treatment of oral care, respiratory disorder, asthma, lung disorders. The scientific name of this sacred basil is osmium sanctum. Ayurveda has been described in terms of its infinite miraculous use. Here is a little information about the holy basil. Let's know holy basil leaf health benefits.